Value-based insurance design in medicare

Applied Health Economics and Health Policy

Volumn 7, Issue 3, 2009, Pages 149-154

  Encinosa, William E ^a  

^a AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BORTEZOMIB;

COST CONTROL; DRUG COST; DRUG USE; HEALTH INSURANCE; HUMAN; MEDICARE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; PURCHASING; REIMBURSEMENT; REVIEW; VALUE BASED INSURANCE DESIGN;

COST SHARING; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; MEDICARE PART D; MEDICATION ADHERENCE; PREVENTIVE HEALTH SERVICES; QUALITY ASSURANCE, HEALTH CARE; UNITED STATES;

EID: 70349900243     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/bf03256148     Document Type: Review

References (34)

1. Levy H, Weir D. Take-up of Medicare Part D: results from the Health and Retirement Survey [NBER working paper 14692]. 2009 Jan [online]. Available from URL: http:// www.nber.org/papers/w14692 [Accessed 2009 Sep 15]
2. Centers for Medicare and Medicaid Services. 2009 enrollment information [online]. Available from URL: http:// www.cms.hhs.gov/PrescriptionDrugCovGenIn/ [Accessed 2009 Jun 24]
3. Medicare Payment Advisory Commission. Report to the Congress: Medicare payment policy. Washington, DC: MEDPAC, 2009 Mar
4. Pedan A, Lu J, Varasteh L. Assessment of drug consumption patterns for Medicare Part D patients. Am J Manag Care 2009; 15 (5): 323-327
5. Kaiser Family Foundation, Health Research and Educational Trust. Employer health benefits: annual survey. Menlo Park (CA): Kaiser Family Foundation, 2006
6. Frank RG, Newhouse JP. Should drug prices be negotiated under Part D of Medicare? And if so, how? Health Aff 2008; 27 (1): 33-42
7. Bach P, McClellan M. The first months of the prescription-drug benefit: a CMS update. JAMA 2006 Jun 1; 354 (22): 2312-2314 (Pubitemid 43801275)
8. Dor A, Encinosa W. Does cost-sharing affect compliance? The case of prescription drugs [NBER working paper 10738]. 2004 Sep [online]. Available from URL: http:// www.nber.org/papers/w10738 [Accessed 2009 Sep 15]
9. Value based benefit design: building a research agenda. National Business Coalition on Health Conference; 2008 Nov 12; Washington, DC
10. Fuhrmans V. A radical prescription. Wall Street J 2004 May 10; R3-4
11. Michael EC, Rosen AB, Fendrick AM. Value-based insurance design by abandoning the archaic principle that all services must cost the same for all patients, we can move to a high-value health system. Health Aff 2007 March/April; 26 (2): w195-203
12. Chernew M, Encinosa W, Hirth R. Optimal health insurance: the case of multiple treatment options. J Health Econ 2000; 19: 585-609
13. Zweifel P. Bonus options in health insurance. London: Kluwer, 1995
14. Lewis C. Blue Shield of California quietly explores value-based design. Cal Health Plan Anal 2009 Spring; 8 (2): 1-4
15. Murphy L, Carloss J, Brown RE, et al. Value-based insurance design in the Medicare prescription drug benefit: an analysis of policy options. Avalere Health LLC 2009 Mar [online]. Available from URL: http://www.avalere health.net/wm/show.php?c=1&id=806 [Accessed 2009 Sep 15]
16. Medicare Payment Advisory Commission. Report to the Congress: improving incentives in the Medicare program. Washington, DC: MEDPAC, 2009 June
17. US Senate Bill S. 1040. Seniors' medication copayment reduction act of 2009 [online]. Available from URL: http:// www.govtrack.us/congress/bill.xpd? bill=s111-1040 [Accessed 2009 Sep 15]
18. Dor A. Optimal price rules, administered prices and sub-optimal prevention: evidence from a Medicare program. J Regul Econ 2004; 25 (1): 81-104 (Pubitemid 39072581)
19. Fendrick AM, Smith DG, Chernew ME, et al. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care 2001; 7 (9): 861-867
20. Dor A, Encinosa W. How does cost sharing affect drug purchases? Insurance regimes in the private market for prescription drugs. J Econ Manage Strat. In press
21. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care 2005; 11 (11): 730-740
22. Hsu J, Price M, Huang J, et al. Unintended consequences of caps on Medicare drug benefits. N Engl J Med 2006; 354 (22): 2349-2359 (Pubitemid 43801280)
23. Rice T, Matsuoka KY. The impact of cost-sharing on appropriate utilization and health status: a review of the literature on seniors. Medi Care Res Rev 2004; 61 (4): 415-452 (Pubitemid 39491928)
24. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations withmedication andmedical utilization and spending and health. JAMA 2007; 298 (1): 61-69, E1-18 (Pubitemid 47026771)
25. Gaynor M, Li J, Vogt WB. Substitution spending offsets, and prescription drug benefit design. Forum Health Econ Policy 2007; 10 (2): 1-31
26. Chandra A, Gruber J, McKnight R. Patient cost-sharing hospitalization offsets, and the design of optimal health insurance for the elderly [NBER working paper no. 12972], 2007 Mar [online]. Available from URL: http://www. nber.org/papers/w12972 [Accessed 2009 Sep 15]
27. Encinosa W, Bernard D, Dor A. Do prescription drugs reduce hospitalizations and costs? American Society of Health Economists Conference; 2004 Jun 6; Madison (WI)
28. White House. A significant breakthrough to assist our seniors [online]. Available from URL: http://www.whitehouse. gov/blog/A-Significant-Breakthrough- to-Assist-Our-Seniors/ [Accessed 2009 Jun 22]
29. Cramer JA. Overview of methods to measure and enhance patient compliance. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press, 1991; 3-10
30. Rovelli M, Palmeri D, Vossler E, et al. Noncompliance in organ transplant recipients. Transplant Proc 1989; 21 (1 Pt 1): 833-834
31. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions. JAMA 2002; 288 (22): 2868-2879
32. Bach P. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009; 360 (6): 626-633
33. US FDA. NME drug and new biologic approvals in 2007 [online]. Available from URL: http://www.fda.gov/Drugs/ DevelopmentApprovalProcess/ HowDrugsareDevelopedand Approved/DrugandBiologicApprovalReports/NMEDrug andNewBiologicApprovals/ucm081690.htm [Accessed 2009 Sep 15]
34. Garber AM, McClellan MB. Satisfaction guaranteed: 'payment by results' for biologic agents. N Engl J Med 2007; 357 (16): 1575-1577